Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 14/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13767275 | 0.87 | HSD11B1 (0.43) | HSD11B1LMNAHTTHPGDSMN1; SMN2 | |
| SCHEMBL13767055 | 0.87 | HSD11B1 (0.42) | HSD11B1LMNAHTT | |
| SCHEMBL13767303 | 0.86 | HSD11B1 (0.42) | HSD11B1LMNAHTTHPGDSMN1; SMN2 | |
| SCHEMBL13767015 | 0.86 | HSD11B1 (0.40) | HSD11B1LMNAHTT | |
| SCHEMBL13767291 | 0.86 | HSD11B1 (0.41) | HSD11B1LMNAHTTHPGDSMN1; SMN2 | |
| SCHEMBL13767008 | 0.86 | HSD11B1 (0.46) | HSD11B1LMNAHTT | |
| SCHEMBL13767285 | 0.85 | KDM4E (0.41) | HSD11B1LMNAHTTHPGDSMN1; SMN2 | |
| SCHEMBL13767267 | 0.84 | HSD11B1 (0.41) | HSD11B1LMNAHTTHPGDSMN1; SMN2 | |
| SCHEMBL13767072 | 0.84 | HSD11B1 (0.40) | HSD11B1LMNAHTT | |
| SCHEMBL13767286 | 0.84 | HSD11B1 (0.39) | HSD11B1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324265-B2 | Heterocyclic compounds having type I 11β hydroxysteroid dehydrogenase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-12-04 | — | — | US | disclosed |
| US-8324265-B2 | Heterocyclic compounds having type I 11β hydroxysteroid dehydrogenase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-12-04 | — | — | US | disclosed |
| US-20090170832-A1 | HETEROCYCLIC COMPOUNDS HAVING TYPE I 11beta HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2009-07-02 | — | — | US | disclosed |
| US-20090170832-A1 | HETEROCYCLIC COMPOUNDS HAVING TYPE I 11beta HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170832-A1 | HETEROCYCLIC COMPOUNDS HAVING TYPE I 11beta HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY | HSD17B1, HSD11B1, HSD3B1 | HSD11B1 2/4885LMNA 2271/4885HTT 3719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.